AUPH News and Press, Aurinia Pharmaceuticals Inc From 05/02/24

2024-05-02 06:09:37 ET More on Aurinia Pharma Aurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum Going Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024 Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed Aurinia Pharm...

Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and extending the trend of consistent growth in LUPKYNIS ® (voclosporin) sales Rapidly com...

2024-05-01 11:43:59 ET More on Aurinia Pharma Aurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum Going Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024 Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed Aurinia gains...

In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and the need for frequent screening and appropriate management, including an innov...

2024-04-30 13:00:10 ET Summary Aurinia Pharmaceuticals Inc. full-year 2023 sales of Lupkynis increased by 53% year over year to $158.5 million. Updated label provides several advantages for sales of Lupkynis going forward, like no need for monthly kidney monitoring 1-year after tr...

2024-04-30 08:42:34 ET More on Aurinia Pharma Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024 Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon Au...

New data showing sustained complete renal response with LUPKYNIS through three years Monthly kidney function assessment no longer required after first year of treatment Safety profile remains unchanged and is aligned with the safety findings in the AURORA clinical program ...

2024-04-18 11:26:22 ET Summary Aurinia Pharmaceuticals has the potential for up to 80-100% upside by the end of 2024. The company's focus on cost savings and a single product commercial biotech strategy is positive. The potential increase in US sales and from international mar...

NOTE: The new presentation time for Aurinia’s presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conferences is 4:00 to 4:30 PM Eastern Time. This event is presentation only. Webcast Details remain the same. The updated release reads: Aurinia Pharmaceuticals ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the first quarter of 2024 on Thursday, May 2, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ...